Shenzhen Hepalink Pharmaceutical : 2020 AGM Circular

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about any of the contents of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Shenzhen Hepalink Pharmaceutical Group Co., Ltd., you should at once hand this circular together with the proxy form to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

2020 WORK REPORT OF THE BOARD OF DIRECTORS

2020 WORK REPORT OF THE BOARD OF SUPERVISORS

2020 ANNUAL REPORT AND ITS SUMMARY, H SHARES RESULTS ANNOUNCEMENT, H SHARES 2020 ANNUAL REPORT, 2020 CORPORATE GOVERNANCE REPORT AND 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2020 FINAL FINANCIAL REPORT

2020 PROFIT DISTRIBUTION PROPOSAL

RE-APPOINTMENT OF AUDITORS

2021-2023 SHAREHOLDER RETURN THREE-YEAR PLAN

APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2021

PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT

USING PART OF THE UNEMPLOYED H SHARES IPO PROCEEDS

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

AND

NOTICE OF THE 2020 ANNUAL GENERAL MEETING

A letter from the Board is set out on pages 3 to 7 of this circular. A notice of the annual general meeting (the "AGM") of the Company to be held at 2:30 p.m. (Hong Kong time) on Wednesday, May 26, 2021 at Ballroom, 2/F, L'Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, PRC, is being dispatched to the H Share Shareholders together with this circular.

H Share Shareholders who intend to appoint a proxy to attend the AGM shall complete and return the proxy form in accordance with the instructions printed thereon. The proxy form must be signed by you or your attorney duly authorised in writing or, in case of a legal person, must either be executed under its seal or under the hand of its director or other attorney duly authorised to sign the same. If the proxy form is signed by an attorney of the appointor, the power of attorney authorising that attorney to sign, or other document of authorisation, must be notarized.

In the case of joint holders of the H Shares, only the holder whose name stands first in the register of members of the H Shares of the Company shall alone be entitled to vote at the AGM, either in person or by proxy in respect of such H Shares.

For H Share Shareholders, please return the proxy form together with any documents of authority to the H Shares registrar of the Company in Hong Kong, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible, and in any event not later than 24 hours before the time appointed for holding the AGM or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish.

April 23, 2021

CONTENTS

				Page
DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	1
LETTER FROM THE BOARD . . . . . . . . . . . . . . . . . . . . . . . . . . .	3
1.	Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	4
2.	Matters to be considered at the Annual General Meeting
	i.	2020	Work Report of the Board of Directors . . . . . . . . . . . . . . . .	4
	ii.	2020	Work Report of the Board of Supervisors . . . . . . . . . . . . . . .	4
	iii.	2020	Annual Report and its Summary, H Shares Results Announcement,
		H Shares 2020 Annual Report, 2020 Corporate Governance Report and
		2020 Environmental, Social and Governance Report . . . . . . . . . . . .	5
	iv.	2020	Final Financial Report . . . . . . . . . . . . . . . . . . . . . . .	5
	v.	2020	Profit Distribution Proposal . . . . . . . . . . . . . . . . . . . . .	5
	vi.	Re-appointment of Auditors . . . . . . . . . . . . . . . . . . . . . . .	5
	vii.	2021-2023 Shareholder Return Three-Year Plan . . . . . . . . . . . . . . .	6
	viii.	Application for Credit Line and Providing Guarantee to Certain Banks for 2021 . .	6
	ix.	Purchase of Wealth Management Products and Cash Flow Management Using
		Part of the Unemployed H Shares IPO Proceeds . . . . . . . . . . . . . .	6
	x.	Proposed Election of Mr. Zhang Bin as an Executive Director . . . . . . . . .	6
3.	Annual General Meeting and Closure of Register of Members of H Shares . . . . . .	6
4.	Voting by Poll . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	7
5.	Recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	7
APPENDIX - BIOGRAPHY OF PROPOSED EXECUTIVE DIRECTOR . . . . . . . . .	8
NOTICE OF THE 2020 ANNUAL GENERAL MEETING . . . . . . . . . . . . . . . .	9

Note: If there are any discrepancies between the Chinese version and the English version of this circular, the Chinese version shall prevail.

- i -

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

"Articles of Association"	the articles of association of the Company
or "Articles"
"A Share(s)"	domestic share(s) issued by the Company, with a nominal value of RMB1.00
	each, which are subscribed for or credited as paid in Renminbi and are listed
	for trading on the Shenzhen Stock Exchange
"Board"	the board of directors of the Company
"Company"	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業
	集團股份有限公司), a joint stock company incorporated in the PRC with
	limited liability, whose A Shares are listed on the Shenzhen Stock Exchange
	(stock code: 002399) and whose H Shares are listed on the main board of the
	Hong Kong Stock Exchange (stock code: 9989)
"AGM"	the annual general meeting of the Company to be convened and held on May
	26, 2021
"Director(s)"	director(s) of the Company
"Group"	the Company and its subsidiaries
"HK dollars"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"H Share(s)"	overseas listed foreign share(s) in the share capital of the Company with
	a nominal value of RMB1.00 each, which are subscribed for and traded in
	Hong Kong dollars and listed on the Main Board of the Hong Kong Stock
	Exchange
"H Shares IPO Proceeds"	net proceeds from the listing of the H Shares
"H Share	the holder(s) of the H Share(s)
Shareholder(s)"
"Latest Practicable Date"	April 20, 2021, being the latest practicable date for the purpose of
	ascertaining certain information contained in this circular prior to its
	publication
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of
	Hong Kong Limited
"PRC"	the People's Republic of China, which, for the purpose of this circular,
	excludes Hong Kong, the Macau Special Administrative Region and Taiwan

- 1 -

DEFINITIONS

"RMB" or "Renminbi"

"Share(s)"

"Shareholder(s)"

"Shenzhen Stock   Exchange"

"Stock Exchange" or

• "Hong Kong Stock
• Exchange"

Renminbi, the lawful currency of the PRC

ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising the A Share(s) and H Share(s)

holder(s) of the Share(s)

the Shenzhen Stock Exchange (深圳證券交易所)

The Stock Exchange of Hong Kong Limited

"Supervisor(s)"

member(s) of the Company's Board of Supervisors

- 2 -

LETTER FROM THE BOARD

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

Executive Directors:	Registered office in the PRC:
Mr. Li Li (Chairman of the Board)	No. 21 Langshan Road
Ms. Li Tan (Deputy General Manager)	Nanshan District
Mr. Shan Yu (General Manager)	Shenzhen
Mr. Sun Xuan (Vice Chairman)	PRC
Independent non-executive Directors:	Principal place of business
Dr. Lu Chuan	in Hong Kong:
Mr. Chen Junfa	Room 4724, 47/F
Mr. Wang Zhaohui	Sun Hung Kai Centre
	30 Harbour Road
	Wan Chai, Hong Kong

April 23, 2021

To the Shareholders

Dear Sir or Madam,

2020 WORK REPORT OF THE BOARD OF DIRECTORS

2020 WORK REPORT OF THE BOARD OF SUPERVISORS

2020 ANNUAL REPORT AND ITS SUMMARY, H SHARES RESULTS ANNOUNCEMENT H SHARES 2020 ANNUAL REPORT, 2020 CORPORATE GOVERNANCE REPORT AND 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2020 FINAL FINANCIAL REPORT

2020 PROFIT DISTRIBUTION PROPOSAL

RE-APPOINTMENT OF AUDITORS

2021-2023 SHAREHOLDER RETURN THREE-YEAR PLAN

APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2021

PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT

USING PART OF THE UNEMPLOYED H SHARES IPO PROCEEDS

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

AND

NOTICE OF THE 2020 ANNUAL GENERAL MEETING

- 3 -

LETTER FROM THE BOARD

1. INTRODUCTION

The purpose of this circular is to provide you (among other things) with the information to enable you to make informed decision on whether to vote for or against the resolutions to be proposed at the AGM:

At the AGM, ordinary resolutions will be proposed to approve, among others:

1. The 2020 Work Report of the Board of Directors
2. The 2020 Work Report of the Board of Supervisors
3. The 2020 Annual Report and its Summary, H Shares Results Announcement, H Shares 2020 Annual Report, 2020 Corporate Governance Report and 2020 Environmental, Social and Governance Report
4. The 2020 Final Financial Report
5. The 2020 Profit Distribution Proposal
6. The re-appointment of Auditors

At the AGM, special resolutions will be proposed to approve, among others:

1. The 2021-2023 Shareholder Return Three-Year Plan
2. The application for credit line and providing guarantee to certain banks for 2021
3. The purchase of wealth management products and cash flow management using part of the unemployed H Shares IPO Proceeds

At the AGM, ordinary resolution will be proposed to approve:

1. Proposed appointment of executive Director

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

1. 2020 Work Report of the Board of Directors

Please refer to the relevant part in the 2020 Annual Report of the Company published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021 for the main content of the 2020 Work Report of the Board of Directors.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

1. 2020 Work Report of the Board of Supervisors

Please refer to the 2020 Work Report of the Board of Supervisors of the Company published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

- 4 -

LETTER FROM THE BOARD

1. 2020 Annual Report and its Summary, H Shares Results Announcement, H Shares 2020 Annual Report, 2020 Corporate Governance Report and 2020 Environmental, Social and Governance Report

Please refer to the 2020 Annual Report and its Summary of the Company published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

Please refer to the H Shares Results Announcement, H Shares 2020 Annual Report and 2020 Corporate Governance Report of the Company published on the website of the Hong Kong Stock Exchange. The 2020 Environmental, Social and Governance Report of the Company will be published on the website of the Hong Kong Stock Exchange in due course.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

1. 2020 Final Financial Report

Please refer to the 2020 Final Financial Report of the Company published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

1. 2020 Profit Distribution Proposal

The Board has proposed a distribution of RMB0.15 (tax inclusive) per share as final dividend for the year ended December 31, 2020 (the "Final Dividend").

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

Subject to the approval of the 2020 Profit Distribution Proposal by the Shareholders at the AGM, the Final Dividend is expected to be distributed no later than July 26, 2021 to H Shares Shareholders whose names appear on the register of H Shares Shareholders on June 4, 2021. The Final Dividend is denominated and declared in Renminbi. The Final Dividend payable to the H Shares Shareholders shall be paid in Hong Kong dollars. The amount of Hong Kong dollars payable will be calculated on the basis of the average closing exchange rates for Hong Kong dollars as announced by the Foreign Exchange Trading Centre of the PRC one calendar week prior to the approval of the Final Dividend at the AGM.

1. Re-appointmentof Auditors

The Company proposed to re-appoint Ernst & Young Hua Ming LLP and Ernst & Yong as the domestic financial and internal control auditor of the Company for the year of 2021 and Ernst & Young as the overseas financial report auditor of the Company for the year of 2021.

The proposed re-appointment of auditors was deliberated on and approved at the meeting of the Board held on March 29, 2021 and is hereby proposed to the AGM as an ordinary resolution for consideration and approval.

- 5 -

LETTER FROM THE BOARD

vii. 2021-2023 Shareholder Return Three-Year Plan

Please refer to the Shareholder Dividend Return Plan for the Next Three Years (2021-2023) published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as a special resolution for consideration and approval.

viii. Application for Credit Line and Providing Guarantee to Certain Banks for 2021

Please refer to the announcement on application for credit line and providing guarantee to certain banks for 2021 of the Company published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as a special resolution for consideration and approval.

1. Purchase of Wealth Management Products and Cash Flow Management Using Part of the Unemployed H Shares IPO Proceeds

Please refer to the announcement on purchase of wealth management products and cash flow management using part of the unemployed H Shares IPO Proceeds published on the websites of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange on March 29, 2021.

This resolution has been considered and approved at the meeting of the Board held on March 29,

2021 and is hereby proposed to the AGM as a special resolution for consideration and approval.

1. Proposed Election of Mr. Zhang Bin as an Executive Director

Please refer to the announcement related to the proposed appointment of an executive Director published on the websites of the Shenzhen Stock Exchange and Hong Kong Stock Exchange on April 19, 2021.

The biography of Mr. Zhang Bin, the candidate of executive Director, is set out in the Appendix section of this circular.

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

A notice of the AGM is set out on pages 9 to 10 of this circular. A proxy form to be used at the AGM or any adjournment thereof is also enclosed herein and published on the website of the Hong Kong Stock Exchange. H Share Shareholders who intend to appoint a proxy to attend the AGM shall complete, sign and return the proxy form in accordance with the instructions printed thereon.

For H Share Shareholders, the proxy form, and if the proxy form is signed by a person under a power of attorney or other authority on behalf of the appointor, a notarized copy of that power of attorney or other authority, must be delivered to the Company's H Shares registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not less than 24 hours before the time for holding the AGM or any adjournment thereof in order for such documents to be valid.

- 6 -

LETTER FROM THE BOARD

The register of members of the H Shares will be closed from May 21, 2021 to May 26, 2021 (both days inclusive), during which period no transfer of H Shares will be effected. For unregistered H Share Shareholders who intend to attend the AGM, all share certificates and the relevant transfer documents must be lodged with the H Shares registrar of the Company in Hong Kong, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not later than 4:30 p.m. on May 20, 2021. H Share Shareholders whose names appear on the register of members of the H Shares on May 21, 2021 will be entitled to attend and vote at the AGM.

The register of members of the Company's H Shares will be closed from June 1, 2021 to June 4, 2021, both days inclusive, during which period no transfer of H Shares will be registered, in order to determine the shareholders' entitlement to receive the Final Dividend. The H Share Shareholders who wish to receive the Final Dividend should lodge the transfer documents and relevant share certificates with the Company's H Shares registrar in Hong Kong, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong on or before 4:30 p.m. on May 31, 2021. H Share Shareholders whose names appear on the register of members of the H Shares on June 4, 2021 will be entitled to receive the Final Dividend, which is subject to the approval of 2020 Profit Distribution Proposal by the Shareholders at the AGM.

4. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Hong Kong Listing Rules, all votes of the Shareholders at the AGM must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. As such, the resolutions proposed at the AGM will be voted by poll.

5. RECOMMENDATION

The Directors consider that all resolutions proposed at the AGM are in the interests of the Company and its Shareholders as a whole. As such, the Directors recommend the Shareholders to vote in favour of all resolutions to be proposed at the AGM.

By order of the Board

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

Chairman

- 7 -

APPENDIX	BIOGRAPHY OF PROPOSED EXECUTIVE DIRECTOR

Biography of Mr. Zhang Bin, the proposed executive Director:

Mr. Zhang Bin, born in 1977 and aged 44, with Chinese nationality, is entitled to permanent residence in the United States. Mr. Zhang holds a master's degree, being a non-practicing member of the Chinese Institute of Certified Public Accountants and a non-practicing member of American Institute of Certified Public Accountants. From June 2005 to August 2015, Mr. Zhang worked at KPMG's offices in China and the United States, and served as an inspection expert of the Public Company Accounting Oversight Board of the United States from August 2015 to February 2016. Since April 2016, Mr. Zhang has been serving as the financial controller of the Company and concurrently as director of our wholly- owned subsidiaries/sub-subsidiaries, Hepalink USA, SPL Acquisition Corp. and Cytovance Biologics, Inc. ("Cytovance") since February 2018. He has been the CEO of Cytovance since October 2020, and his primary responsibilities include overseeing the financial activities of the Company, participating in the implementation of the Company's business strategies, especially in the fields of innovative drugs and CDMO.

The proposed appointment of Mr. Zhang as an executive Director is subject to the approval by the Shareholders at the AGM, with effect from the date of AGM and shall end on the expiry of the term of the fifth session of the Board. He can be re-elected upon the expiry of his term according to the Articles of Association.

After the appointment as an executive Director is approved by the Shareholders at the AGM, the Company will enter into a director's service contract with Mr. Zhang. Mr. Zhang will not receive any remuneration for services he will provide as an executive Director. However, he will continue to receive remunerations as the financial controller of the Company. For the year ended December 31, 2020, Mr. Zhang received a total annual remuneration of approximately RMB4,390 thousand from the Company.

As of the Latest Practicable Date, Mr. Zhang participated in the Company's Employee Share Scheme

1. (the "Scheme II") and had a 3.04% interest in the underlying 15,118,035 A Shares held by the asset manager for the benefit of the participants of the Scheme II.

Save as disclosed above, Mr. Zhang does not hold any other position in the Company or its subsidiaries, nor serve as a director of any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date on which he is appointed. And he does not have any other material appointments and professional qualifications.

To the best knowledge of the Company, save as disclosed above, Mr. Zhang has no relationship with any Director, Supervisor, senior management, substantial shareholder or controlling shareholder of the Company, nor any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations referred by Part XV of the Securities and Futures Ordinance, and nor any disciplinary sanction taken by the China Securities Regulatory Commission or any other relevant agency or the Hong Kong Stock Exchange.

Save as disclosed above, there is no other information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor any other matter in connection with Mr. Zhang's appointment that need to be brought to the attention of the Shareholders.

- 8 -

NOTICE OF THE 2020 ANNUAL GENERAL MEETING

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

NOTICE OF THE 2020 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2020 annual general meeting (the "AGM") of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") will be held at 2:30 p.m. on Wednesday, May 26, 2021 at Ballroom, 2/F, L'Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated April 23, 2021.

ORDINARY RESOLUTIONS

To consider and pass the following ordinary resolutions by way of non-cumulative voting:

1. The resolution regarding the 2020 Work Report of the Board of Directors of the Company;
2. The resolution regarding the 2020 Work Report of the Board of Supervisors of the Company;
3. The resolution regarding the 2020 Annual Report and its Summary, H Share Results Announcement, H Shares 2020 Annual Report, 2020 Corporate Governance Report and 2020 Environmental, Social and Governance Report of the Company;
4. The resolution regarding the 2020 Final Financial Report of the Company;
5. The resolution regarding the 2020 Profit Distribution Proposal of the Company;
6. The resolution regarding the re-appointment of auditors of the Company;

SPECIAL RESOLUTIONS

To consider and pass the following special resolutions by way of non-cumulative voting:

1. The resolution regarding the 2021-2023 Shareholder Return Three-Year Plan of the Company;
2. The resolution regarding the application for credit line and providing guarantee to certain banks for 2021 of the Company;
3. The resolution regarding the purchase of wealth management products and cash flow management using part of the unemployed H Shares IPO Proceeds of the Company; and

- 9 -

NOTICE OF THE 2020 ANNUAL GENERAL MEETING

ORDINARY RESOLUTION

To consider and pass the following ordinary resolution by way of non-cumulative voting:

10. The resolution regarding the appointment of executive director of the Company.

By order of the Board

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

Chairman

Shenzhen, PRC

April 23, 2021

Notes:

1. The register of members of the Company's H shares will be closed from May 21, 2021 to May 26, 2021 (both days inclusive), during which period no transfer of H shares can be registered. In order for H share shareholders to be qualified to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H Shares registrar of the Company, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, no later than 4:30 p.m. on May 20, 2021 for registration.
   The H share shareholders whose names appear on the register of members of the Company's H shares on May 21, 2021 are entitled to attend and vote at the AGM.
2. H share shareholders who are entitled to attend and vote at the AGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder.
3. The instrument appointing a proxy must be in writing under the hand of a shareholder or his attorney duly authorised in writing. If the shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
4. In order to be valid, the proxy form must be deposited, for H share shareholders, to the H Shares registrar of the Company, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong not less than 24 hours before the time for holding the AGM. If the proxy form is signed by a person under a power of attorney or other authority, a notarized copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude the shareholders from attending and voting in person at the AGM or any adjourned meetings should they so wish.
5. Shareholders shall produce their identification documents and supporting documents in respect of the shares of the Company held when attending the AGM. If corporate shareholders appoint authorised representative to attend the AGM, the authorised representative shall produce his/her identification documents and a notarized copy of the relevant authorisation instrument signed by the board of directors or other authorised parties of the corporate shareholders or other notarized documents allowed by the Company. Proxies shall produce their identification documents and the proxy form signed by the shareholders or their attorney when attending the AGM.
6. The AGM is expected to take for less than half a day. Shareholders attending the AGM shall be responsible for their own travel and accommodation expenses.
7. All voting at the AGM will be conducted by poll.
8. References to times and dates of this notice are to Hong Kong times and dates.

- 10 -